Quoin Pharmaceuticals, Ltd. filed a Form D with the Securities and Exchange Commission on 2025-10-23.
Quoin Pharmaceuticals, Ltd. filed a Form D notice of an exempt securities offering with the SEC on October 23, 2025. Quoin Pharmaceuticals, Ltd. trades on Nasdaq as QNRX. The filing reports $105.25M sold. Its industry group is Pharmaceuticals. It names Michael Myers (Executive Officer, Director), Sally Lawlor (Executive Officer), Denise Carter (Executive Officer, Director) (SEC Form D, October 23, 2025).
In its own words: “We are relentlessly focused on developing therapeutic products to address a range of rare diseases.” (quoinpharma.com, checked November 1, 2026)
Is this your company?
Sell to companies like Quoin Pharmaceuticals, Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-23 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Quoin Pharmaceuticals, Ltd.
Free to see. No signup.
More on the people and the money behind Quoin Pharmaceuticals, Ltd., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Quoin Pharmaceuticals, Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Quoin Pharmaceuticals, Ltd. raises, hires or launches. No email unless you switch it on.
Watch Quoin Pharmaceuticals, Ltd. →Get the full cited report on Quoin Pharmaceuticals, Ltd.
What the filing shows about Quoin Pharmaceuticals, Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Quoin Pharmaceuticals, Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Quoin Pharmaceuticals, Ltd.'s address as 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Quoin Pharmaceuticals Ltd. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Quoin Pharmaceuticals, Ltd. See pricing
Quoin Pharmaceuticals, Ltd. is a registered filer with the SEC (CIK 1671502) and has filed since 2025-10-23. 2 filings are on record, the latest on 2026-09-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Quoin Pharmaceuticals, Ltd.'s Form D of 2025-10-23 names Michael Myers, Sally Lawlor, Denise Carter and 5 more as its officers, directors or promoters.
Its new offerings report $155.26M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers
By form type: 6-K ×176 · 8-K ×61 · 4 ×51 · 424B3 ×47 · CORRESP ×21 · EFFECT ×19 · SC 13G ×14 · UPLOAD ×14, and others.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-10 | open |
| 8-K | 2026-09-10 | open |
| 4 | 2026-09-01 | open |
| 4 | 2026-09-01 | open |
| 4 | 2026-09-01 | open |
| 4 | 2026-09-01 | open |
| 4 | 2026-08-28 | open |
| 4 | 2026-08-28 | open |
| 8-K | 2026-08-28 | open |
| 8-K | 2026-08-20 | open |
What the filing shows about Quoin Pharmaceuticals, Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Quoin Pharmaceuticals, Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Quoin Pharmaceuticals, Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 10 most recent of 567 filings on CIK 0001671502, filed as Quoin Pharmaceuticals Ltd.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in L3. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
The Investor Relations website contains information about Quoin Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Michael Myers is named as Executive Officer and Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Sally Lawlor is named as Executive Officer on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Denise Carter is named as Executive Officer and Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Joseph Cooper is named as Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
James Culverwell is named as Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Dennis Langer is named as Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Natalie Leong is named as Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
Michael Sember is named as Director on the Form D that Quoin Pharmaceuticals, Ltd. filed with the SEC on 23 October 2025, one of 8 people that filing names.
8 people named on the filing — 3 holding an executive role and 5 as directors only.
Named as of the 2025-10-23 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Quoin Pharmaceuticals, Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind Quoin Pharmaceuticals, Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (investors.quoinpharma.com).
Each opens in a new tab, filled in for Quoin Pharmaceuticals, Ltd.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Washington, DC
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/quoin-pharmaceuticals-ltd-form-d-25000001